WO2019208913A1 - Composition comprenant un extrait de sanguisorba officinalis l. en tant que principe actif pour favoriser la croissance osseuse - Google Patents

Composition comprenant un extrait de sanguisorba officinalis l. en tant que principe actif pour favoriser la croissance osseuse Download PDF

Info

Publication number
WO2019208913A1
WO2019208913A1 PCT/KR2019/001170 KR2019001170W WO2019208913A1 WO 2019208913 A1 WO2019208913 A1 WO 2019208913A1 KR 2019001170 W KR2019001170 W KR 2019001170W WO 2019208913 A1 WO2019208913 A1 WO 2019208913A1
Authority
WO
WIPO (PCT)
Prior art keywords
bone growth
promoting
fat milk
growth
composition
Prior art date
Application number
PCT/KR2019/001170
Other languages
English (en)
Korean (ko)
Inventor
고병섭
박선민
육진아
김혜진
양현
Original Assignee
한국한의학연구원
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한국한의학연구원 filed Critical 한국한의학연구원
Publication of WO2019208913A1 publication Critical patent/WO2019208913A1/fr

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/105—Plant extracts, their artificial duplicates or their derivatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/73—Rosaceae (Rose family), e.g. strawberry, chokeberry, blackberry, pear or firethorn
    • A61K36/739—Sanguisorba (burnet)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2200/00—Function of food ingredients
    • A23V2200/30—Foods, ingredients or supplements having a functional effect on health
    • A23V2200/306—Foods, ingredients or supplements having a functional effect on health having an effect on bone mass, e.g. osteoporosis prevention

Definitions

  • the present invention relates to a composition for promoting bone growth comprising Sanguisorba officinalis L. extract as an active ingredient, more specifically, pharmaceutical or food that can promote bone growth by administering or ingesting children or adolescents in the growing phase. It relates to a composition.
  • Bone is a tissue composed of calcium and phosphorus, and calcium phosphate complex, collagen fiber, glycoprotein, and proteoglycan are the main constituents, and the organs that make up and support the body. It plays a role in protecting internal organs and supports muscle movement, and also plays a role in constituting and maintaining a shape, but bone marrow can generate blood, an oxygen carrier of the body.
  • Osteoblasts one of the types of bone cells, secrete collagen and alkaline phosphatase to form bones.
  • Alkaline phosphatase does not yet know what function it performs, but it has high bone cell production. It is known to show high levels in the plasma of patients.
  • osteoclasts are cells that destroy bones, and break down bones to serve to release phosphate and calcium into plasma.
  • Bone growth is made by the interaction of osteoclasts and osteoblasts. When bone is absorbed by osteoclasts, osteoblasts can be combined again with calcium and phosphorus and bone growth. When osteoblasts have higher activity than osteoclasts, bone growth occurs, and in the opposite case, bone destruction occurs, which can lead to osteoporosis. When osteoblast activity is higher than osteoclasts, growth hormone is secreted at the growth stage, such as children and adolescence.
  • Calcium and phosphorus two major constituents of bone, are present in the form of two ions in the complex of bones, but in ionized form in the serum when they move. Depending on the concentration of calcium ions in the blood, calcium resorption is increased or excreted and homeostasis is maintained.
  • the hormones that affect growth include insulin, thyroid hormone, and sex hormones, among which hormones are secreted from the anterior lobe of the pituitary gland, which grows the body, promotes bone calcification, increases protein synthesis, and immunity. It plays a role in promoting action.
  • Growth hormone is associated with blood sugar because glucose is the energy source available to the brain, the main driver of growth. Excessive growth hormone secretion can lead to high blood sugar levels, which can lead to diabetes.
  • An object of the present invention is to solve the above problems, when administered to a child or adolescents in the growing phase as a medicine, food, etc. in bone growth and growth plate growth of children or adolescents in the growing phase without side effects of metabolic disease or obesity induction Not only to promote bone growth, but also to provide a composition for promoting bone growth, including a fat milk extract that has the effect of maintaining or increasing bone density.
  • a pharmaceutical composition for promoting bone growth including a fat milk extract as an active ingredient.
  • the fat milk extract may be extracted by water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
  • the pharmaceutical composition may be prepared from any one of granules, powders, tablets, coated tablets, capsules, solutions, syrups, juices, suspensions, emulsions, drops and injection solutions.
  • the pharmaceutical composition may be to induce bone growth by enhancing one or more signaling selected from a transforming growth factor beta (TGF- ⁇ ) receptor and a wnt receptor.
  • TGF- ⁇ transforming growth factor beta
  • the pharmaceutical composition may be for promoting bone growth of growing children or adolescents.
  • the pharmaceutical composition may be for promoting bone growth of obese children or adolescents.
  • a food composition for promoting bone growth including a fat milk extract as an active ingredient.
  • the fat milk extract may be extracted by water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof.
  • the food composition may be to induce bone growth by enhancing one or more signaling selected from a transforming growth factor beta (TGF- ⁇ ) receptor and a wnt receptor.
  • TGF- ⁇ transforming growth factor beta
  • the food composition may be for promoting bone growth of growing children or adolescents.
  • the food composition may be for promoting bone growth of obese children or adolescents.
  • the food composition may be prepared from any one of granules, powders, tablets, coated tablets, capsules, solutions, syrups, juices, suspensions, and emulsions.
  • It provides a health functional food for promoting bone growth comprising the food composition.
  • the health functional food may be prepared by adding the fat milk extract to any one food material selected from beverages, teas, spices, gum and confectionery.
  • a method of preparing a pharmaceutical composition for promoting bone growth comprising the step of extracting fat milk with water, alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof to prepare a fat milk extract.
  • Concentration under reduced pressure may be further performed after the step.
  • a method for preparing a food composition for promoting bone growth comprising the step of extracting fat milk with water, an alcohol having 1 to 4 carbon atoms, or a mixed solvent thereof to prepare a fat milk extract.
  • Concentration under reduced pressure may be further performed after the step.
  • a method for preparing a health functional food for promoting bone growth wherein the food composition is added to any one food material selected from beverages, teas, spices, gum and confectionery to produce a health functional food.
  • a novel use of a fat milk extract for the manufacture of a medicament for promoting bone growth is provided.
  • the medicine for promoting bone growth may be a medicine for preventing or treating a growth disorder.
  • a method for treating a growth disorder comprising administering to a patient with a growth disorder a pharmaceutical composition comprising a fat milk extract as an active ingredient.
  • Bone growth promoting composition comprising the oil extract of the present invention, when administered as a medicine, food, etc. to children or adolescents in the growing phase without the side effects of metabolic diseases or obesity induction, bone length growth, growth plate expansion of children or adolescents in the growing phase
  • bone density is also effective to maintain or increase. It also promotes bone growth and can be used for the prevention or treatment of growth disorders.
  • 6 and 7 show the results of mRNA expression analysis of wnt signaling-related genes according to Experimental Example 4.
  • Figure 8 shows the weight measurement results of the white paper after the dietary supply according to Experimental Example 5.
  • FIG. 11 is a microscope image of H-E staining of a growth plate in a joint area of a white paper according to Experimental Example 7.
  • FIG. 11 is a microscope image of H-E staining of a growth plate in a joint area of a white paper according to Experimental Example 7.
  • FIG. 12 is a graph comparing lengths of growth parts in a growth plate according to Experimental Example 7.
  • FIG. 12 is a graph comparing lengths of growth parts in a growth plate according to Experimental Example 7.
  • Figure 13 is a graph comparing the length of the hypertrophy in the growth plate according to Experimental Example 7.
  • FIG. 14 is a graph comparing the entire joint length according to Experimental Example 7.
  • Figure 15 is the result of measuring the bone density change of the lumbar spine (Lumbar spine) according to Experimental Example 8.
  • Figure 16 is the result of measuring the bone density change of femur according to Experimental Example 8.
  • Fat milk extract of the present invention can be used as an active ingredient of the pharmaceutical composition for promoting bone growth.
  • the fat milk extract promotes bone growth, and thus may be used for the prevention or treatment of growth disorders.
  • the growth disorder can be normal mutant nephropathy or nephropathy secondary to disease.
  • the normal mutant short stature may be familial short stature, constitutional delay in growth, idiopathic short stature in consultation.
  • hypothyroidism secondary to disease may be primary growth disorders (endogenous disorders) or secondary growth disorders (exogenous growth disorders), and the primary growth disorders include osteochondral dysplasia, chromosomal abnormalities (Down syndrome or Turner syndrome), short stature due to unreasonable lightweight infants (delayed growth in the uterus), short stature by Freder-Willy syndrome, short stature by Russell-Silver syndrome, and short stature by Nurnan syndrome. Short stature due to systemic diseases, short stature due to growth hormone deficiency, short stature due to hypothyroidism, short stature due to Cushing's syndrome, and psychosocial dwarfism.
  • the fat milk extract may be extracted using water, an organic solvent or a mixture thereof as an extraction solvent.
  • the kind of organic solvent used at this time and the mixing ratio of water and an organic solvent are not specifically limited.
  • the organic solvent may be one or more solvents selected from the group consisting of lower alcohols, hexane, acetone, ethyl acetate, chloroform, and diethyl ether.
  • the lower alcohol may be an alcohol having 1 to 6 carbon atoms.
  • methanol, ethanol, propanol, butanol, normal-propanol, iso-propanol, normal-butanol, 1-pentanol, 2-butoxyethanol or ethylene glycol may be used as the lower alcohol.
  • Organic solvents include polar solvents such as acetic acid, dimethyl-formamide (DMFO) and dimethyl sulfoxide (DMSO), acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, 2,2,4-trimethylpentane, and decane.
  • polar solvents such as acetic acid, dimethyl-formamide (DMFO) and dimethyl sulfoxide (DMSO), acetonitrile, ethyl acetate, methyl acetate, fluoroalkane, pentane, 2,2,4-trimethylpentane, and decane.
  • nonpolar solvents such as benzene, diethyl ether, diethyl sulfide, chloroform, dichloromethane, 1,2-dichloroethane, anneal, diethylamine, ether, carbon tetrachloride, and THF (Tetrahydrofuran).
  • the fat milk extract of the present invention is interpreted as a concept including both the oil fraction of the fat milk extract, the liquid fraction of the fat milk extract, and the wax fraction of the fat milk extract.
  • the fat milk extract may include any one or more selected from the group consisting of an oil fraction of a fat milk extract, a liquid fraction of a fat milk extract, and a wax fraction of a fat milk extract.
  • the fat milk extract may be a lower alcohol extract of fat milk, preferably an ethanol extract of fat milk.
  • the term 'extract' also includes fractions that additionally fractionate the extract. That is, the fat milk extract includes not only one obtained by using the aforementioned extraction solvent, but also one obtained by additionally applying a purification process thereto. In addition, fractions obtained by passing the extract or fraction through an ultrafiltration membrane having a constant molecular weight cut-off value, separation by various chromatography (manufactured for separation according to size, charge, hydrophobicity or affinity), etc. The fraction obtained through various purification methods described above is also included in the fat milk extract of the present invention.
  • the fat milk extract may be a fraction obtained by re-fractionation of the organic solvent extract of the fat milk with a second organic solvent.
  • the organic solvent extract of the fat milk broadly includes all the oil fraction of the fat milk extract, the liquid fraction of the fat milk extract, the wax fraction of the fat milk extract, and narrowly means the liquid fraction of the fat milk extract. do. Therefore, in one embodiment, the fraction re-fractionated the organic extract of the fat milk with the second organic solvent may mean a fraction that re-fractionated the liquid fraction of the fat milk extract with the second organic solvent.
  • the fat milk extract may be a fraction obtained by re-fractionation of the lower alcohol extract of fat milk with a second organic solvent.
  • the fat milk extract may be a fraction of the ethanol extract of the fat milk re-fractionated with hexane.
  • the fraction of the fat milk extract containing a large amount of fat-soluble components of such fat milk shows a very good effect.
  • the term 'extract' as used herein to refer to the fat milk includes not only the crude extract obtained by treating the extraction solvent to the fat milk, but also processed products of the fat milk extract.
  • the fat milk extract may be prepared in powder form by additional processes such as distillation under reduced pressure and freeze drying or spray drying.
  • the fat milk extract of the present invention has a meaning broadly also includes a fat milk processed product, such as a fat milk powder, formulated to administer the fat milk itself to an animal.
  • a fat milk processed product such as a fat milk powder
  • the desired effect can be achieved in the same form as the fat milk processed product.
  • the term 'comprising as an active ingredient' herein means containing an amount sufficient to achieve the efficacy or activity of the fat or milk extract.
  • the fat milk extract in the composition of the invention is for example at least 0.001 mg / kg, preferably at least 0.1 mg / kg, more preferably at least 10 mg / kg, even more preferably Is at least 100 mg / kg, even more preferably at least 250 mg / kg, most preferably at least 1 g / kg. Since the fat milk extract has no side effects on the human body even when excessively administered as a natural product, the quantitative upper limit of the fat milk extract contained in the composition of the present invention can be selected and performed by those skilled in the art within an appropriate range.
  • the pharmaceutical composition of the present invention may be prepared using a pharmaceutically suitable and physiologically acceptable adjuvant in addition to the active ingredient, and the adjuvant may include excipients, disintegrants, sweeteners, binders, coating agents, swelling agents, lubricants, lubricants. Agents, flavors and the like can be used.
  • the pharmaceutical composition may be preferably formulated into a pharmaceutical composition comprising one or more pharmaceutically acceptable carriers in addition to the active ingredient described above for administration.
  • Formulation forms of the pharmaceutical composition may be granules, powders, tablets, coated tablets, capsules, suppositories, solutions, syrups, juices, suspensions, emulsions, drops or injectable solutions.
  • the active ingredient may be combined with an oral, nontoxic, pharmaceutically acceptable inert carrier such as ethanol, glycerol, water and the like.
  • suitable binders, lubricants, disintegrants and coloring agents may also be included in the mixture.
  • Suitable binders include, but are not limited to, natural and synthetic gums such as starch, gelatin, glucose or beta-lactose, corn sweeteners, acacia, trackercance or sodium oleate, sodium stearate, magnesium stearate, sodium Benzoate, sodium acetate, sodium chloride and the like.
  • Disintegrants include, but are not limited to, starch, methyl cellulose, agar, bentonite, xanthan gum, and the like.
  • Acceptable pharmaceutical carriers in compositions formulated in liquid solutions are sterile and physiologically compatible, including saline, sterile water, Ringer's solution, buffered saline, albumin injectable solutions, dextrose solution, maltodextrin solution, glycerol, ethanol and One or more of these components may be mixed and used, and other conventional additives such as antioxidants, buffers and bacteriostatic agents may be added as necessary. Diluents, dispersants, surfactants, binders and lubricants may also be added in addition to formulate into injectable formulations, pills, capsules, granules or tablets such as aqueous solutions, suspensions, emulsions and the like.
  • the pharmaceutical composition of the present invention may be administered orally or parenterally, and in the case of parenteral administration, it may be administered by intravenous injection, subcutaneous injection, intramuscular injection, intraperitoneal injection, transdermal administration, or the like, and preferably, oral administration.
  • Suitable dosages of the pharmaceutical compositions of the present invention vary depending on factors such as the formulation method, mode of administration, age, weight, sex, morbidity, condition of food, time of administration, route of administration, rate of excretion and response to reaction, and usually The skilled practitioner can readily determine and prescribe a dosage effective for the desired treatment or prophylaxis.
  • the daily dosage of the pharmaceutical composition of the present invention is 0.001-10 g / kg.
  • compositions of the present invention may be prepared in unit dosage form by formulating with a pharmaceutically acceptable carrier and / or excipient according to methods which can be easily carried out by those skilled in the art. Or by incorporating into a multi-dose container.
  • the formulation may be in the form of a solution, suspension or emulsion in an oil or an aqueous medium, or may be in the form of extracts, powders, granules, tablets or capsules, and may further include a dispersant or stabilizer.
  • the present invention also provides a food composition for promoting bone growth comprising a fat milk extract as an active ingredient.
  • the food composition according to the present invention may be formulated in the same manner as the pharmaceutical composition, used as a functional food, or added to various foods.
  • examples of the food to which the composition of the present invention may be added include beverages, alcoholic beverages, confectionary, diet bars, dairy products, meat, chocolates, pizza, ramen noodles, other noodles, gums, ice creams, vitamin complexes, and health supplements. Etc.
  • the food composition of the present invention may include a fat milk extract or a fat milk powder as an active ingredient, as well as ingredients that are commonly added during food production, and include, for example, proteins, carbohydrates, fats, nutrients, seasonings and flavoring agents. Include.
  • examples of the above carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose, oligosaccharides and the like; And sugars such as conventional sugars such as polysaccharides such as dextrin, cyclodextrin and the like and xylitol, sorbitol, erythritol.
  • natural flavoring agents such as tauumatin, stevia extract (for example rebaudioside A, glycyrrhizin, etc.) and synthetic flavoring agents (saccharin, aspartame, etc.) can be used.
  • synthetic flavoring agents sacharin, aspartame, etc.
  • citric acid, liquid fructose, sugar, glucose, acetic acid, malic acid, fruit juice, and various plant extracts may be further included in addition to the fat milk extract of the present invention.
  • the present invention provides a health functional food comprising a food composition for promoting bone growth, comprising the extract as an active ingredient.
  • Health functional food is a food prepared by adding fat milk extract or fat milk powder to food materials such as beverages, teas, spices, chewing gum, confectionery, or by encapsulating, powdering, and suspension. Means to bring, but unlike the general medicine has the advantage that there is no side effect that can occur when taking a long-term use of the drug as a raw material.
  • the health functional food of the present invention thus obtained is very useful because it can be consumed on a daily basis.
  • the addition amount of the fat milk extract or the fat milk powder in such a health functional food cannot be uniformly prescribed
  • a health functional food in the form of pills, granules, tablets or capsules it is usually added in the range of 0.1 to 100% by weight, preferably 0.5 to 80% by weight.
  • the dietary supplement of the present invention may be in the form of pills, tablets, capsules or beverages.
  • the present invention also provides the use of a fat milk extract for the manufacture of a medicament or food for promoting bone growth.
  • the fat milk extract or the fat milk powder may be used for promoting bone growth.
  • the present invention also provides a method for promoting bone growth, comprising administering an effective amount of a fat milk extract to a mammal.
  • mammal refers to a mammal that is the subject of treatment, observation or experimentation, preferably human.
  • the term “effective amount” means an amount of an active ingredient or pharmaceutical composition that induces a biological or medical response in a tissue system, animal or human, as contemplated by a researcher, veterinarian, doctor or other clinician, Amounts that induce alleviation of the symptoms of the disease or disorder. It will be apparent to those skilled in the art that the effective amount and frequency of administration for the active ingredients of the present invention will vary depending on the desired effect. Therefore, the optimal dosage to be administered can be readily determined by one skilled in the art and includes the type of disease, the severity of the disease, the amount of active ingredients and other ingredients contained in the composition, the type of formulation, and the age, weight, general health of the patient. It may be adjusted according to various factors including the condition, sex and diet, time of administration, route of administration and the rate of secretion of the composition, the duration of treatment, and the drugs used simultaneously.
  • compositions comprising a fat or oil extract as an active ingredient in the treatment method of the present invention may be administered in a conventional manner through oral, rectal, intravenous, intraarterial, intraperitoneal, intramuscular, intrasternal, transdermal, topical, intraocular or intradermal routes. May be administered.
  • the filtrate was concentrated using a vacuum condenser and then lyophilized to prepare a fat milk extract.
  • Treatment group was treated with 1 ⁇ g / mL and 5 ⁇ g / mL fat milk extract to MG63 cells cultured in cultured osteoblasts, and after 1 hour treated with 100 ⁇ g / mL palmitate to induce cytotoxicity, After 24 hours, 10 ⁇ l of 3- (4,5-dimethythiazol-2yl) -2,5-diphenyl tetrazolium bromide (MTT) solution was added to the control group and the fat treatment group, and then incubated in a CO 2 incubator for 4 hours.
  • MTT 3- (4,5-dimethythiazol-2yl) -2,5-diphenyl tetrazolium bromide
  • DMSO dimethyl sulfozide
  • the fat milk extract inhibited the cytotoxicity caused by palmitate, inhibited apoptosis and increased cell survival in a concentration-dependent manner, and the high fat milk extract improved cell viability compared to the control group.
  • MG63 cells cultured in the same manner as in Experimental Example 1 were prepared, and ALP (alkaline phosphatase) activity was measured in the following manner.
  • MG63 cells were aliquoted into 96 well plates, and then cultured in a CO 2 incubator divided into an untreated control group and a fat milk extract treatment group of Preparation Example 1.
  • the milk fat extract of Preparation Example 1 was treated at a concentration of 1 ⁇ g / ml and 5 ⁇ g / ml, respectively.
  • supernatants of cultured cells were collected and ALP activity was measured at 405 nm using a kit of Abcam (ab83369).
  • the absorbance of the standard the relationship between the protein concentration and the absorbance was prepared and applied to calculate the protein concentration of the cell solution for each treatment group.
  • the ALP concentration was divided by the protein concentration and applied to the following relationship to calculate the ALP activity, and the results are shown in FIG. 2.
  • ALP showed the degree of cell destruction, but in cell experiments, osteoblasts were destroyed before new cells were formed, so increasing ALP activity resulted in increased cell growth, and ALP activity was slightly increased in the 5 ⁇ g / ml fat-treated group. I did not show a statistically significant difference.
  • TGF- ⁇ and wnt signaling are activated. MRNA expression of the gene was measured.
  • TGF- ⁇ signaling leads to BMP-2-> pSMAD1 / 5/7-> SMAD4-> bone growth, in which DKK1 acts as a mechanism to inhibit TGF- ⁇ .
  • 6 and 7 show the results of mRNA expression analysis of wnt signaling-related genes in the control group, the 1 ⁇ g / mL fat milk treatment group, and the 5 ⁇ g / mL fat milk treatment group of G-63 cells treated under the same conditions as in Experimental Example 1. Shown in
  • the diet was provided in the same manner as in Example 1 except that the milk extract did not provide 100 mg / kg body weight (0.015% diet) and 300 mg / kg body weight (0.045% diet).
  • the diet was provided in the same manner as in Example 1, except that the fat milk extract was not provided.
  • the diet was provided in the same manner as in Example 1, except that subcutaneous injection of 20 ⁇ g / kg body weight (Eutropin-L Life Science) was used instead of the fat milk extract.
  • FIG. 8 is a graph comparing body weights of 4 male rats after 4 weeks of feeding AIN-93G feed adjusted to only 43 calories of fat content.
  • the femur length was not significantly different from the negative control group in the negative control group after feeding the diet for 4 weeks, but in Example 2, it was statistically significantly longer than the negative control group.
  • Example 2 it was statistically significantly longer than the negative control group.
  • FIG. 11 HE microscopic images of growth plates in the joint area of the white paper are shown in FIG. 11, and graphs comparing the lengths of the proliferation part and the hypertrophy part in the growth plate are shown in FIGS. 12 and 13. The graph is shown in FIG.
  • the negative control group showed a small growth plate area and irregular cells.
  • the positive control group showed a wide growth plate area and the cell nuclei were regularly arranged. Can see.
  • the growth plate region was widened in a concentration-dependent manner and the cells were regularly arranged as compared to the negative control group.
  • bone mineral density (BMD) of the lumbar spine and bone density of the femur were measured and shown in FIGS. 15 and 16, respectively.
  • BMD bone mineral density
  • the ALP concentration indicating the degree of bone degradation was lower in Example 2 than in the negative control group, and showed a similar value to the positive control group.
  • the concentration of osteocalcin in serum which is an indicator of the degree of bone synthesis, was higher in Example 2 than in the negative control group and was not statistically different from the positive control group.
  • the length of femur and tibia is longer in Example 2 than that of the negative control and positively correlated with serum osteocalcin concentration.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Mycology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Biotechnology (AREA)
  • Epidemiology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Polymers & Plastics (AREA)
  • Food Science & Technology (AREA)
  • Nutrition Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medical Informatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

La présente invention concerne une composition comprenant un extrait de Sanguisorba officinalis L. en tant que principe actif pour favoriser la croissance osseuse. Lorsqu'elle est administrée sous forme de médicaments ou d'aliments à des enfants et à des adolescents, qui se trouvent dans la période de croissance dans leur vie, la composition favorisant la croissance osseuse comprenant un extrait de Sanguisorba officinalis L. selon la présente invention présente les effets suivants : l'augmentation de la longueur osseuse et l'expansion des physes pour favoriser la croissance osseuse, ainsi que le maintien ou l'augmentation de la densité minérale osseuse chez les enfants et les adolescents.
PCT/KR2019/001170 2018-04-26 2019-01-28 Composition comprenant un extrait de sanguisorba officinalis l. en tant que principe actif pour favoriser la croissance osseuse WO2019208913A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR10-2018-0048594 2018-04-26
KR1020180048594A KR102106400B1 (ko) 2018-04-26 2018-04-26 지유를 유효성분으로 포함하는 뼈 성장 촉진용 조성물

Publications (1)

Publication Number Publication Date
WO2019208913A1 true WO2019208913A1 (fr) 2019-10-31

Family

ID=68294623

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2019/001170 WO2019208913A1 (fr) 2018-04-26 2019-01-28 Composition comprenant un extrait de sanguisorba officinalis l. en tant que principe actif pour favoriser la croissance osseuse

Country Status (2)

Country Link
KR (1) KR102106400B1 (fr)
WO (1) WO2019208913A1 (fr)

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06183985A (ja) * 1992-12-16 1994-07-05 Suntory Ltd 吸収性骨疾患の予防・治療剤
JP2004067634A (ja) * 2002-08-09 2004-03-04 Pola Chem Ind Inc 育毛素材及びそれを含有する皮膚外用剤
WO2006063515A1 (fr) * 2004-12-14 2006-06-22 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Utilisation de radix sanguisorbae et de son extrait pour la preparation d’un medicament visant a accroitre la numeration erythrocytaire et le taux d’hemoglobine
KR101465568B1 (ko) * 2014-09-16 2014-11-28 한국방송통신대학교 산학협력단 오이풀 추출물을 이용한 반추동물 메탄 저감용 사료첨가제
KR20150003046A (ko) * 2013-06-28 2015-01-08 연세대학교 산학협력단 Ｗｎｔ/β-카테닌 신호전달계와 관련된 질병을 치료하는 천연물의 용도

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR100818204B1 (ko) 2007-09-06 2008-04-02 (주)뉴메드 겨우살이 추출물을 유효성분으로 함유하는 골길이 성장촉진용 조성물
KR101737854B1 (ko) 2015-02-23 2017-05-19 한림대학교 산학협력단 오이풀 추출물을 유효성분으로 포함하는 당뇨 및 당뇨합병증 예방 또는 개선용 조성물
KR101781121B1 (ko) 2016-04-04 2017-09-22 한국 한의학 연구원 복합 생약추출물의 발효물을 포함하는 장질환의 예방 또는 치료용 조성물

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06183985A (ja) * 1992-12-16 1994-07-05 Suntory Ltd 吸収性骨疾患の予防・治療剤
JP2004067634A (ja) * 2002-08-09 2004-03-04 Pola Chem Ind Inc 育毛素材及びそれを含有する皮膚外用剤
WO2006063515A1 (fr) * 2004-12-14 2006-06-22 Chengdu Di'ao Pharmaceutical Group Co., Ltd. Utilisation de radix sanguisorbae et de son extrait pour la preparation d’un medicament visant a accroitre la numeration erythrocytaire et le taux d’hemoglobine
KR20150003046A (ko) * 2013-06-28 2015-01-08 연세대학교 산학협력단 Ｗｎｔ/β-카테닌 신호전달계와 관련된 질병을 치료하는 천연물의 용도
KR101465568B1 (ko) * 2014-09-16 2014-11-28 한국방송통신대학교 산학협력단 오이풀 추출물을 이용한 반추동물 메탄 저감용 사료첨가제

Also Published As

Publication number Publication date
KR102106400B1 (ko) 2020-05-06
KR20190124525A (ko) 2019-11-05

Similar Documents

Publication Publication Date Title
WO2012165731A1 (fr) Nouvelle utilisation du riz, du son de riz ou d'un extrait de balle en tant qu'antagoniste de récepteur de l'histamine
WO2018194309A1 (fr) Composition pharmaceutique contenant de l'indirubine en tant que substance active
WO2014058142A1 (fr) Composition pharmaceutique contenant un extrait d'aster glehni en tant que principe actif pour la prévention et le traitement de l'obésité et de troubles métaboliques
WO2015002391A1 (fr) Composition présentant une fonction d'atténuation du syndrome prémenstruel et des douleurs menstruelles
WO2016060426A1 (fr) Composition contenant un extrait de dolichos lablab l. comme principe actif pour prévenir ou soulager une stéatose hépatique non alcoolique
WO2018174448A1 (fr) Composition pour le traitement et la prévention du syndrome climactérique contenant un extrait médicinal végétal combiné d'atractylis, de mori fructus, de lyciet commun, de longane, d'achyranthes, d'écorce d'eucommia et d'asperge de cochinchine merr. comme ingrédient actif, et son utilisation
WO2016153211A2 (fr) Procédé de préparation d'extrait d'écorce d"agrumes et composition pour prévenir, soulager ou traiter une lésion hépatique
WO2019209061A1 (fr) Composition favorisant la croissance osseuse comprenant de l'allium fistulosum linn en tant que principe actif
WO2015108394A1 (fr) Composition cosmétique contenant un composé dérivé de l'hydroxypyranone pour stimuler la différenciation des adipocytes
WO2012020991A2 (fr) Composition pour prévenir et soulager une maladie du cerveau comprenant des acides aminés de la soie et la tyrosine comme ingrédients actifs
WO2017116045A1 (fr) Composition destinée à prévenir et traiter un trouble du climatère contenant des extraits de dendropanax morbifera lev. comme principe actif
WO2020235828A1 (fr) Composition pour l'inhibition d'ostéoclastes contenant un extrait d'agastache rugosa en tant que principe actif, et son utilisation
WO2019208914A1 (fr) Composition comprenant portulaca oleracea l. en tant que principe actif pour favoriser la croissance osseuse
WO2012134172A2 (fr) Composition contenant, comme ingrédient actif, une fraction d'acétate d'éthyle de schisandra chinensis baill, ou wuweizisu c séparée de la fraction, pour prévenir ou traiter l'obésité
WO2017082478A1 (fr) Composition pharmaceutique visant à prévenir ou traiter l'ostéoporose et contenant un extrait de germe de soja
WO2019208913A1 (fr) Composition comprenant un extrait de sanguisorba officinalis l. en tant que principe actif pour favoriser la croissance osseuse
WO2017082479A1 (fr) Composition pharmaceutique destinée à la prévention ou au traitement de l'obésité comprenant un extrait embryonnaire de fève germée
WO2021040416A1 (fr) Composition pharmaceutique pour prévenir ou traiter la perte osseuse induite par des maladies métaboliques osseuses, comprenant un extrait d'artemisia scoparia en tant que principe actif
WO2022215925A1 (fr) Composition favorisant l'ostéogenèse, comprenant des vésicules extracellulaires dérivées du lait
WO2010008150A2 (fr) Composition pour prévenir ou traiter l'ostéoporose qui contient comme principe actif un mélange d'extraits de saururus chinensis et de scutellaria baicalensis
WO2014157803A1 (fr) Composition comprenant un extrait de mollusques et crustacés comme principe actif qui est destinée au soulagement de l'anxiété, à l'amélioration de convulsant, à une action sédative ou à l'induction ou à l'amélioration du sommeil
WO2021080298A1 (fr) Composition contenant enterococus faecalis en guise de principe actif pour la prévention ou le traitement de l'obésité ou de syndromes métaboliques induits par cette dernière
KR101084942B1 (ko) 천우슬을 이용한 관절염 치료제
WO2020246671A1 (fr) Composition pour favoriser la croissance osseuse comprenant de la feuille de carotte en tant que principe actif
WO2018190638A1 (fr) Composition pour la prévention ou le traitement de maladies cornéennes, contenant un extrait de glycine max

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 19793307

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 19793307

Country of ref document: EP

Kind code of ref document: A1